


SOCIETY FOR IMMUNOTHERAPY OF CANCER

2017 ACCOMPLISHMENTS REPORT



Society for Immunotherapy of Cancer



The **SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)** is the world's leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. A 501(c)(3) not-for-profit organization, SITC was established in 1984 to exchange, encourage and promote information about the promise of immunotherapy for patients with cancer.

Since our inception more than three decades ago, SITC has experienced tremendous growth in terms of membership, scope of our scientific initiatives, educational programs and collaborative outreach activities. SITC strives to be a unifying force and the collective voice of the entire cancer immunotherapy field.


MISSION STATEMENT

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

VISION

SITC aims to make cancer immunotherapy a standard of care and the word “**CURE**” a reality for cancer patients everywhere.

OUR GLOBAL CONSTITUENCY OF NEARLY 2,000 CLINICIANS AND BASIC SCIENTISTS,
AND REPRESENTATIVES FROM ACADEMIA, GOVERNMENT AND INDUSTRY, SPANS 17
MEDICAL SPECIALTIES ENGAGED IN RESEARCH AND TREATMENT OF AT LEAST A DOZEN
TYPES OF CANCER.



2017 has been a record-setting year, confirming SITC as the leader in the cancer immunotherapy field. Using the 2016-2018 Strategic Plan as the framework, SITC has made incredible strides to help position cancer immunotherapy as a valuable treatment modality in the fight against cancer.



CULTIVATE MEANINGFUL RELATIONSHIPS

SITC IS COMMITTED TO INCREASING INTERACTIONS WITH GOVERNMENT AGENCIES, AS WELL AS PARALLEL AND ALLIED ORGANIZATIONS FROM AROUND THE GLOBE, TO MAKE THE GOAL OF A CURE FOR CANCER A REALITY.



STAND UP
TO CANCER



SITC HAS CULTIVATED MEANINGFUL RELATIONSHIPS WITH THESE ORGANIZATIONS:



SERVE AS THE LEADING RESOURCE

SITC CONTINUES TO PROVIDE THE BEST LIVE AND ONLINE EDUCATION, SCIENTIFIC EXCHANGE AND NETWORKING OPPORTUNITIES TO ENRICH THE CANCER IMMUNOTHERAPY FIELD.

SITC's Annual Meeting & Pre-Conference Programs continues record growth as evidenced by a projected 45% increase in attendance from 2016 to 2017 and a 21% increase in abstract submissions from 2016 to 2017.



45% INCREASE



21% INCREASE



Launched in May 2017, SITC connectED is an online learning portal offering cancer immunotherapy-focused live and on-demand educational resources.

New in 2017, the SITC Annual Meeting expanded its clinical track by renaming it as the physician/nurse/pharmacist track in order to increase educational offerings for practitioners interested in the clinical application of cancer immunotherapy.

SITC's Advances in Cancer Immunotherapy™ series is successfully educating community clinicians, nurses, pharmacists and emergency physicians on integrating immunotherapy into clinical practice, with an astounding 99% of survey respondents from this regional program series indicating they would recommend the program to others.

In March 2017, SITC convened over 80 researchers, physicians, nurses and industry representatives to develop consensus recommendations on management of immune-related adverse events resulting from immune checkpoint inhibitor therapy. The resulting guideline manuscript has been submitted for publication in the *Journal for Immunotherapy of Cancer* (JITC).

SITC is on pace to reach 7,100 learners through SITC-led educational programs over the past year — a 51% increase over the previous year.

Since its launch in May 2017, SITC connectED has reached 3,000 learners through the 47 educational activities in addition to 4,000 visitors who have accessed almost 700 available resources.

SITC entered into its fourth year of a strategic partnership with Medscape Oncology offering 59 free online CME-certified educational activities with experts in the field of immunotherapy to over 100,000 learners.

An updated third edition of the “Patient Resource Cancer Guide: Understanding Cancer Immunotherapy” has been distributed for free to 7,500 patients and medical professionals, and digital copies of the guide are available in SITC's CONNECT Resource Library.

As of the end of 2017, SITC's Cancer Immunotherapy Guideline series includes guidelines on the treatment of renal cell, prostate and bladder carcinomas and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An updated guideline on management of cutaneous melanoma, and a new guideline for non-small cell lung carcinoma (NSCLC), are in development. All guidelines will have an associated digital and printed pocket guide for quick reference in the clinic.

SITC published the first textbook of its kind, “Cancer Immunotherapy Principles and Practice”. This comprehensive reference work covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation.


To broaden SITC's reach in cancer immunotherapy education, in 2017 SITC provided cancer immunotherapy content and expert speakers for 25 educational programs organized by other associations, educating approximately 6,700 professionals at these events.

CREATE A

NETWORK

OF STAKEHOLDERS

THROUGH MEANINGFUL ENGAGEMENT WITH STAKEHOLDERS, SITC ACTS AS THE MAIN HUB OF INFORMATION AND PROVIDES OPPORTUNITIES FOR INTERACTION AMONG KEY LEADERS IN THE FIELD.



The inaugural SITC Sparkathon retreat attracted 29 brilliant emerging leaders to create collaborative projects, which will solve the hurdles facing the cancer immunotherapy field over the next year. This 2017 Sparkathon class will present the results of their field-altering projects at SITC 2018.

The 2017-2018 Advances of Cancer Immunotherapy™ series, featuring 15 live programs, 12 online modules, 30 post-meeting webinars and 15 online communities, is jointly provided by Postgraduate Institute for Medicine and SITC in collaboration with the American Academy of Emergency Medicine and the Association of Community Cancer Centers.

The *Journal for ImmunoTherapy of Cancer* (JITC) is now indexed in six major databases, including PubMed, PubMed Central, MEDLINE, Directory of Open Access Journals, Elsevier's Scopus database and Clarivate Analytics' Science Citation Index Expanded (SCIE).

The thought leader video, *SITC – Leading the Cancer Immunotherapy Evolution*, detailing its role in the cancer immunotherapy evolution, launched on YouTube.

Through enhanced member benefits, cultivation of key constituency groups and expansion of membership to the entire cancer care team in 2016, the society has nearly doubled its membership base in the last three years. New member categories including: Nurses, Nurse Practitioners, Physician Assistants, Allied Health Professionals, Patients and Patient Advocates now account for 8% of SITC's membership.

Over 600 individual volunteers have helped shape discussions that guide progress in the field.

CONNECT-A-COLLEAGUE

37% of new members say they heard about the society through "word of mouth," with nearly 30% joining the society due to a referral from a specific member.



ADVANCE THE SCIENCE GLOBALLY

SITC UTILIZES GLOBAL PARTNERSHIPS, BRIDGES GEOGRAPHICAL DISTANCE THROUGH TECHNOLOGY AND DEVELOPS TARGETED EDUCATION IN AN EFFORT TO ADVANCE THE SCIENCE AND APPLICATION OF CANCER IMMUNOTHERAPY WORLDWIDE.



SITC has reached nearly 3,000 people internationally through collaborative educational programs in nine countries outside of the United States including three new countries – Algeria, Czech Republic and Sweden.

Journal for ImmunoTherapy of Cancer (JITC) editors represent a variety of countries and specialties within the field of tumor immunology and cancer immunotherapy.

The Global Immunoscore Validation Project, led by SITC, united medical centers from around the world in an effort to validate the immunoscore as a prognostic tool in patients with colon cancer. The primary manuscript reporting final data analyses is now complete and will be published in due course.

SITC is proud to announce the formation of the International Advisory Committee. The purpose of this committee is to build new relationships with international cancer immunotherapy organizations, with the aim of providing international SITC educational activities to further stimulate immunotherapy research and global membership recruitment.

VISITORS TO THE *JOURNAL FOR IMMUNOTHERAPY OF CANCER* (JITC)
REPRESENT NEARLY 190 COUNTRIES FROM AROUND THE GLOBE, A 31%
INCREASE OVER 2016.

Global
Immunoscore
Validation Project

SEEK THE BEST RESEARCH

SITC CHALLENGES THE STATUS QUO AND SEEKS OUT INNOVATIVE RESEARCH THAT DRIVES THE FIELD INTO THE FUTURE. NONE OF THIS WOULD HAVE BEEN POSSIBLE WITHOUT THE *FORWARD FUND*, WHICH SUPPORTS THE DEVELOPMENT OF YOUNG INVESTIGATORS IN THE FIELD TO CULTIVATE THE NEXT GENERATION OF CANCER IMMUNOTHERAPY EXPERTS.



ADVOCATE FOR
IMMUNOTHERAPY
FUNDING



The *Forward Fund* met the
Challenge Grant and launched
the first Sparkathon!

Journal for ImmunoTherapy of Cancer (JITC)

The number of article accesses in 2017 for the *Journal for ImmunoTherapy of Cancer* (JITC) are on pace to nearly double 2016's total accesses, showing that JITC is a preferred resource for cancer immunotherapy research.

2017 *Journal for ImmunoTherapy of Cancer* (JITC) article citations are pacing 68% ahead of 2016 and continue to increase.

Funding for Immunotherapy

SITC proposed appropriation report language to urge NCI to put a higher priority on immunotherapy, especially regarding basic research on mechanisms of action as well as training for young and mid-career researchers. The proposal was accepted and included in the Senate's FY 2018 Labor-HHS Appropriations bill.

SITC continues to expand its influence and reach into advocating for biomedical research. SITC and AACR partnered on the first immunotherapy focused Hill Briefing seeking support for basic science research funding.

SITC 2017 features a Grant Writing Workshop, during which experienced study section reviewers and chairs will provide students, postdoctoral fellows and early career scientists with the tools and insight into securing vital funding to advance their immunotherapy careers.

In 2017, SITC inspired 70 early career scientists through *Forward Fund* Fellowship, Travel and Sparkathon Awards.

SITC is dedicated to exploring and finding solutions to key scientific questions. In 2017, SITC's scientific committees planned several workshops and published a number of important publications:

Immune Biomarkers Task Force

The Immune Biomarkers Task Force published several manuscripts in the *Journal for ImmunoTherapy of Cancer* (JITC) in 2017. Among these were a report from the 'Immunotherapy Biomarkers 2016: Overcoming the Barriers' meeting, which was held in collaboration with the Center for Cancer Research, National Cancer Institute of the National Institutes of Health. Other publications included: 'Systematic Evaluation of Immune Regulation and Modulation' and 'Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy'. An expanded Task Force will reconvene to plan a 2018 workshop to emerging issues in obtaining and processing biospecimens, identification of new biomarkers and data and specimen sharing.

Combination Immunotherapy Task Force

In February 2017, the Combination Immunotherapy Task Force published a white paper entitled, 'Combination Immunotherapy: A Road Map' in the *Journal for ImmunoTherapy of Cancer* (JITC). The paper provides evidence-based guidance to drive progress in this area and improve on the clinical benefits obtained with single agents.

Cancer Immune Responsiveness Task Force

This new Task Force brings together early career scientists and leaders in immunology, cell biology, genetics, computational biology and other relevant areas, to explore and increase understanding of the immune response to cancer. A workshop in the first half of 2018 will bring together stakeholders to discuss key topics that may inform future drug development.

SOCIETY FOR IMMUNOTHERAPY OF CANCER

BOARD OF DIRECTORS

PRESIDENT (2016-2018)

Lisa H. Butterfield, PhD
University of Pittsburgh

VICE PRESIDENT (2016-2018)

Mario Sznol, MD
Yale University

SECRETARY/TREASURER (2014-2017)

F. Stephen Hodi, Jr., MD
Dana-Farber Cancer Institute

IMMEDIATE PAST PRESIDENT (2016-2018)

Howard L. Kaufman, MD, FACS
Rutgers Cancer Institute of New Jersey

AT-LARGE DIRECTORS

Sandra Demaria, MD (2014-2017)
New York University School of Medicine

Robert L. Ferris, MD, PhD, FACS (2014-2017)

University of Pittsburgh Cancer Institute

Jérôme Galon, PhD (2016-2019)

French National Institute of Health and Medical Research,
Cordeliers Research Center

Samir N. Khleif, MD (2016-2019)

Georgia Regents University Cancer Center

Pamela S. Ohashi, PhD (2016-2019)

Princess Margaret Cancer Centre, University Health Network

Willem W. Overwijk, PhD (2014-2017)

University of Texas, MD Anderson Cancer Center

Charles G. Drake, MD, PhD (2016-2019)

Columbia University Medical Center

Leisha A. Emens, MD, PhD (2016-2019)

Johns Hopkins University

Kristen Hege, MD (2016-2019)

Celgene/UCSF

STAFF

Tara Withington, CAE
Executive Director

Kathryn Agard, CMP
Senior Program Manager

Clarissa Barnes, MS
Instructional Designer

Kathryn Behling
Project Manager

Esther Berkowitz, MBChB, MA
Director of Scientific Affairs

Nadine Couto, CMP
Director of Meetings

Jody Felski
Senior Development Manager

Julie Frinzi
Director of Communications

Cari Grulke, CMP
Meetings Coordinator

Peter Intile, PhD
Medical Writer

Erin Irelan
Communications Manager

Angela Kilbert
Director of Administration

Sara Krizan
Project Manager

Mindon Laue, MA
Development Manager

Claire Leischer, MS
Senior Manager of Online Education

Kim Mitschke
Meetings Manager

Nichole Nikolic
Director of Membership

Erin Pacheco
Program Manager

Andrew Palios
Communications Manager

Andrea Rindo
Managing Editor - JITC

Sharon Rise, MA
Director of Development

Alicia Schuessler, CAE
Director of Education

Jacqueline Smith, MA, MS
Policy & Advocacy Manager

Angie Squiers
Membership Manager

Rosanne Stelpflug, MS
Executive Assistant

Shelby Stone
Online Education Manager

Donnette Tinsley, MSED
Program Manager

Lianne Wiggins
Senior Program Manager

Adam Wise
Digital Comm. Manager

Aliya Zouine
Education Coordinator

JOIN US AS WE ADVANCE THE FIELD OF CANCER IMMUNOTHERAPY



sitcancer.org/join



Society for Immunotherapy of Cancer

SOCIETY FOR
IMMUNOTHERAPY OF
CANCER

555 E. Wells St., Suite 1100

Milwaukee, WI 53202

info@sitcancer.org

sitcancer.org



[@sitcancer](https://twitter.com/sitcancer)



[@sitcancer](https://www.facebook.com/sitcancer)



SITCancer



bit.ly/SITCLink